Skip to main content
. 2019 Jan 1;2019:3905817. doi: 10.1155/2019/3905817

Figure 7.

Figure 7

Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 20%, and the relative risk reduction (RRR) = 15%).